[go: up one dir, main page]

PE20010069A1 - Compuestos derivados de piperidina como inhibidores de renina - Google Patents

Compuestos derivados de piperidina como inhibidores de renina

Info

Publication number
PE20010069A1
PE20010069A1 PE2000000386A PE0003862000A PE20010069A1 PE 20010069 A1 PE20010069 A1 PE 20010069A1 PE 2000000386 A PE2000000386 A PE 2000000386A PE 0003862000 A PE0003862000 A PE 0003862000A PE 20010069 A1 PE20010069 A1 PE 20010069A1
Authority
PE
Peru
Prior art keywords
alcoxyl
piperidine
ilmetoxi
methoxy
phenyl
Prior art date
Application number
PE2000000386A
Other languages
English (en)
Inventor
Volker Breu
Wolfgang Wostl
Eric Vieira
Hans-Peter Marki
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010069A1 publication Critical patent/PE20010069A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA I, DONDE: R1 ES NAFTILO OPCIONALMENTE SUSTITUIDO CON 1-3 ALCOXILO C1-C5; R2 ES FENILO, BENCILO OPCIONALMENTE SUSTITUIDO CON 1-3 HALOGENO, CIANO, ALCOXILO C1-C3, NITRO; R3 ES HIDROXIMETILO, IMIDAZOLILMETILO, TRIAZOLILMETILO, H-[CH(OR4)]2-CH2-, H-[CH(OR4)]2-CH2-O-CH2-, R3a-(CH2)k[CH(OR4)]l-CH2-O-; R3a ES H, OH, IMIDAZOLILO, TRIAZOLILO, ALCOXILO C1-C3, (ALCOXI C1-C3)-ALCOXILO C2-C3, OH-ALCOXILO C2-C3, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3; R4 ES H, ALQUILO C1-C3; k ES 1-2; CUANDO R3a ES H, k ES 0; l ES 1-2. SON COMPUESTOS PREFERIDOS (R)-1-METOXI-3-[(3S,4R,5R)-4-[4-[3-(2-METOXI-BENCILOXI)-PROPOXI]-FENIL]-5-(4-METOXI-NAFTALEN-2-ILMETOXI)-PIPERIDIN-3-ILOXI]-PROPAN-2-OL, (R)-3-[(3S,4R,5R)-4-[4-[3-(2-METOXI-BENCILOXI)-PROPOXI]-FENIL]-5-(4-METOXI-NAFTALEN-2-ILMETOXI)-PIPERIDIN-3-ILMETOXI]PROPANO-1,2-DIOL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA I SON INHIBIDORES DE LA ENZIMA RENINA Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDADES COMO RESTENOSIS, GLAUCOMA, INFARTO CARDIACO, HIPERTENSION, INSUFICIENCIA RENAL, INSUFICIENCIA CARDIACA
PE2000000386A 1999-04-27 2000-04-25 Compuestos derivados de piperidina como inhibidores de renina PE20010069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99108199 1999-04-27

Publications (1)

Publication Number Publication Date
PE20010069A1 true PE20010069A1 (es) 2001-03-03

Family

ID=8238050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000386A PE20010069A1 (es) 1999-04-27 2000-04-25 Compuestos derivados de piperidina como inhibidores de renina

Country Status (35)

Country Link
US (2) US6376672B1 (es)
EP (1) EP1175400B1 (es)
JP (1) JP3808706B2 (es)
KR (1) KR100443684B1 (es)
CN (1) CN1147471C (es)
AR (2) AR018719A1 (es)
AT (1) ATE512949T1 (es)
AU (1) AU763718B2 (es)
BR (1) BR0010080B1 (es)
CA (1) CA2370888C (es)
CO (1) CO5170513A1 (es)
CZ (1) CZ302012B6 (es)
DK (1) DK1175400T3 (es)
EG (1) EG23979A (es)
ES (1) ES2366668T3 (es)
GC (1) GC0000251A (es)
HK (1) HK1045999B (es)
HR (1) HRP20010762A2 (es)
HU (1) HU227764B1 (es)
IL (2) IL146002A0 (es)
JO (1) JO2256B1 (es)
MA (1) MA26787A1 (es)
MX (1) MXPA01010934A (es)
MY (1) MY127894A (es)
NO (1) NO320803B1 (es)
NZ (1) NZ514981A (es)
PE (1) PE20010069A1 (es)
PL (1) PL199895B1 (es)
PT (1) PT1175400E (es)
RS (1) RS51156B (es)
RU (1) RU2213731C2 (es)
TR (1) TR200103095T2 (es)
TW (1) TWI224593B (es)
WO (1) WO2000064873A1 (es)
ZA (1) ZA200108735B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6835686B2 (en) * 2001-07-05 2004-12-28 Millennium Specialty Chemicals Catalyst system and process for rearrangement of epoxides to allylic alcohols
AU2003229746A1 (en) * 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Novel tetrahydropyridine derivatives as renin inhibitors
US20040214832A1 (en) * 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
EP1620403B1 (en) * 2003-04-29 2007-11-28 Actelion Pharmaceuticals Ltd. Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
TW200900399A (en) * 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
WO2005051911A1 (en) * 2003-11-26 2005-06-09 Novartis Ag 4-phenylpiperidine derivatives as renin inhibitors
TW200613274A (en) * 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
ATE551052T1 (de) 2004-10-08 2012-04-15 Novartis Ag Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
EP1707202A1 (de) * 2005-03-31 2006-10-04 Speedel Experimenta AG Organische Verbindungen
TW200722424A (en) * 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
TW200833687A (en) * 2005-03-31 2008-08-16 Speedel Experimenta Ag Substituted piperidines
EP1863763A1 (en) * 2005-03-31 2007-12-12 Speedel Experimenta AG 3,4,5-substituted piperidines as renin inhibitors
EP1897879A3 (en) * 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
CN101151262B (zh) * 2005-03-31 2011-07-06 斯皮德尔实验股份公司 取代的哌啶
GEP20115206B (en) 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
US20080255084A1 (en) * 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
CN101356156B (zh) * 2005-11-14 2012-12-05 生命医药公司 天冬氨酸蛋白酶抑制剂
AU2006332124B2 (en) * 2005-12-30 2011-03-03 Novartis Ag 3 , 5-substitgammaued piperidine compounds as renin inhibitors
TW200804359A (en) * 2006-01-19 2008-01-16 Speedel Experimenta Ag Substituted 4-phenylpiperidines
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
WO2008021552A2 (en) * 2006-08-18 2008-02-21 Duke University Biased ligands and methods of identifying same
EP1911758A1 (en) * 2006-10-04 2008-04-16 Speedel Experimenta AG Phenyl piperidine derivatives for use as renin inhibitors
EP1908761A1 (en) * 2006-10-04 2008-04-09 Speedel Experimenta AG Organic compounds
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
CA2699889A1 (en) * 2007-11-02 2009-05-07 Novartis Ag 4,4-disubstituted piperdines
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
EP2488661B1 (en) 2009-10-14 2014-12-24 Oberbauer, Rainer Acute kidney injury risk testing
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
DK231088D0 (da) 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE3640475A1 (de) 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
EP0594618B1 (en) 1991-06-24 1996-04-24 B.V. Optische Industrie "De Oude Delft" Device for measuring the respiration of a person
WO1997003911A1 (de) 1995-07-24 1997-02-06 Railfix N.V. Elektro-permanentmagnetsystem zum manövrieren von einer magnetischen insbesondere ferromagnetischen last
KR100384979B1 (ko) * 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
WO1999012532A2 (en) * 1997-09-08 1999-03-18 F.Hoffmann-La Roche Ag Piperidine derivatives against malaria
US6376672B1 (en) * 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors

Also Published As

Publication number Publication date
NO20015206D0 (no) 2001-10-25
MY127894A (en) 2006-12-29
NO20015206L (no) 2001-10-25
YU77101A (sh) 2004-09-03
BR0010080A (pt) 2002-01-15
NO320803B1 (no) 2006-01-30
HRP20010762A2 (en) 2005-02-28
HK1045999B (zh) 2004-10-21
US6673931B2 (en) 2004-01-06
JO2256B1 (en) 2004-10-07
CZ302012B6 (cs) 2010-09-08
EP1175400A1 (en) 2002-01-30
HU227764B1 (en) 2012-02-28
TR200103095T2 (tr) 2002-04-22
US6376672B1 (en) 2002-04-23
EG23979A (en) 2008-02-27
GC0000251A (en) 2006-11-01
HUP0203669A2 (hu) 2003-02-28
HK1045999A1 (en) 2002-12-20
CN1349503A (zh) 2002-05-15
PL199895B1 (pl) 2008-11-28
CN1147471C (zh) 2004-04-28
CO5170513A1 (es) 2002-06-27
ZA200108735B (en) 2003-01-23
US20020087002A1 (en) 2002-07-04
EP1175400B1 (en) 2011-06-15
HUP0203669A3 (en) 2003-12-29
CZ20013854A3 (cs) 2002-04-17
BR0010080B1 (pt) 2012-03-20
KR20010109529A (ko) 2001-12-10
KR100443684B1 (ko) 2004-08-09
NZ514981A (en) 2004-02-27
CA2370888C (en) 2005-08-23
AR018719A1 (es) 2001-11-28
TWI224593B (en) 2004-12-01
PL353442A1 (en) 2003-11-17
MA26787A1 (fr) 2004-12-20
DK1175400T3 (da) 2011-07-18
IL146002A (en) 2007-03-08
ATE512949T1 (de) 2011-07-15
IL146002A0 (en) 2002-07-25
MXPA01010934A (es) 2002-05-06
AU763718B2 (en) 2003-07-31
WO2000064873A1 (en) 2000-11-02
ES2366668T3 (es) 2011-10-24
JP2002543063A (ja) 2002-12-17
RU2213731C2 (ru) 2003-10-10
RS51156B (sr) 2010-10-31
JP3808706B2 (ja) 2006-08-16
CA2370888A1 (en) 2000-11-02
AU4296800A (en) 2000-11-10
AR070473A2 (es) 2010-04-07
PT1175400E (pt) 2011-08-11

Similar Documents

Publication Publication Date Title
PE20010069A1 (es) Compuestos derivados de piperidina como inhibidores de renina
RU2386622C2 (ru) Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
PE20010068A1 (es) Compuestos derivados de piperidina como inhibidores de renina
JP4326024B2 (ja) 新規なＮ―７―ヘテロサイクリル―ピロロ［２，３―ｄ］ピリミジンおよびこれらの使用
RU2331642C2 (ru) Новые ингибиторы киназ
FI89916B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-/4-(1-substituerade-4-piperazinyl)butyl/-4-tiazolidinoner
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
NZ597647A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
KR0162656B1 (ko) 7-치환된-헵트-6-엔산 및 -헵탄산과 그의 유도체 및 그의 중간체의 제조방법
RU2342383C2 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5
PE20050421A1 (es) COMPUESTOS DE PIRAZOLO[4,3-d]PIRIMIDINA Y PIRAZOLO[3,4-d]PIRIDINA COMO LIGANDOS DE RECEPTORES DE CANNABINOIDES
NZ513449A (en) Oxamic acids and derivatives as thyroid receptor ligands
PE123499A1 (es) Derivados d-prolina
KR19990028772A (ko) 항진균제, 이를 위한 화합물 및 이의 제조방법
NO177006B (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-R2-R4-substituert-3-R3-CO-1-[(C-tilknyttet-N-hetryl)-(Alk)nÅ-1H-indoler, samt mellomprodukt for bruk i denne
PE20081378A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
NO20053133L (no) Kjemiske forbindelser.
JP2006501201A5 (es)
PE20040698A1 (es) Derivados de isoindolina
WO2022098843A1 (en) Compounds and methods for modulating cdk9 activity
PE20060653A1 (es) Derivados triciclicos condensados como moduladores del receptor 5-ht1
MX9605434A (es) Derivados de di-oxadiazol como agentes antihiperglicemicos.
WO2003011396A1 (en) Tetrahydroindolone and purine derivatives linked to arylpiperazines
ES2944735T3 (es) Compuestos de ciclopentano

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed